{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:14:05Z","timestamp":1774973645666,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.yrtph.2024.105743","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T15:48:01Z","timestamp":1732290481000},"page":"105743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Carcinogenicity assessment of inotersen in Tg.rasH2 mice and Sprague-Dawley rats: Implications for 2\u2032-MOE antisense oligonucleotides"],"prefix":"10.1016","volume":"155","author":[{"given":"Tae-Won","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris N.","family":"Papagiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura S.","family":"Zwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery A.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosie Z.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M.","family":"Hoffmaster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-3227","authenticated-orcid":false,"given":"Archit","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott P.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2024.105743_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2307\/2531856","article-title":"Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples","volume":"44","author":"Bailer","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.yrtph.2024.105743_bib2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/01926230701347330","article-title":"Carcinogenicity evaluation: comparison of tumor data from dual control groups in the CD\u20131 mouse","volume":"35","author":"Baldrick","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1177\/0192623313517772","article-title":"Injection-site malignant fibrous histiocytomas in a pegvisomant carcinogenicity study in SD rats","volume":"42","author":"Bartholomew","year":"2014","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yrtph.2024.105743_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2307\/2532200","article-title":"Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity","volume":"49","author":"Bieler","year":"1993","journal-title":"Biometrics"},{"key":"10.1016\/j.yrtph.2024.105743_bib6","first-page":"1","article-title":"A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium","author":"Bleecker","year":"2023","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.yrtph.2024.105743_bib7","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated safety assessment of 2\u2032-O-methoxyethyl chimeric antisense oligonucleotides in NonHuman primates and healthy human volunteers","volume":"24","author":"Crooke","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yrtph.2024.105743_bib8","first-page":"47","article-title":"Variability in the occurrence of spontaneous lesions in Crl:CD-1\u00ae (ICR) mice related to source","volume":"1","author":"Engelhardt","year":"1996","journal-title":"Pathobiology of the Aging Mouse"},{"key":"10.1016\/j.yrtph.2024.105743_bib11","doi-asserted-by":"crossref","first-page":"15525","DOI":"10.1021\/bi051608t","article-title":"The pathway by which the tetrameric protein transthyretin dissociates","volume":"44","author":"Foss","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.yrtph.2024.105743_bib12","first-page":"305","article-title":"Pharmacokinetic\/pharmacodynamic properties of phosphorothioate 2\u2019 - O-(2-Methoxyethyl)-Modified antisense oligonucleotides in animals and man. Antisense drug technology","volume":"2","author":"Geary","year":"2007","journal-title":"Principles, strategies and applications"},{"key":"10.1016\/j.yrtph.2024.105743_bib13","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yrtph.2024.105743_bib14","first-page":"183","article-title":"Soft tissue tumors including cardiovascular lesions","volume":"2","author":"Greaves","year":"1997"},{"key":"10.1016\/j.yrtph.2024.105743_bib15","series-title":"Monographs on Pathology of Laboratory Animals","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/978-3-642-83749-4_19","article-title":"Fibrous histiocytoma, malignant, subcutis, rat","author":"Greaves","year":"1989"},{"key":"10.1016\/j.yrtph.2024.105743_bib16","series-title":"Tumors of Soft Tissues. Pathology of Tumours in Laboratory Animals, Tumours of the Rat","author":"Greaves","year":"1990"},{"key":"10.1016\/j.yrtph.2024.105743_bib17","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1293\/tox.26.1S","article-title":"Proliferative and non-proliferative lesions of the rat and mouse soft tissue, skeletal muscle and mesothelium","volume":"26","author":"Greaves","year":"2013","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib18","first-page":"468","article-title":"Chemically modified oligonucleotides exhibit decreased immune stimulation in mice","volume":"292","author":"Henry","year":"2000","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.yrtph.2024.105743_bib19","first-page":"327","article-title":"Toxicologic properties of 2\u2019-O-methoxyethyl chimeric antisense inhibitors in animals and man","author":"Henry","year":"2008","journal-title":"Antisense Drug Technology Principles, Strategies, and Applications"},{"key":"10.1016\/j.yrtph.2024.105743_bib20","series-title":"Full Prescribing Information for Tegsedi","year":"2018"},{"key":"10.1016\/j.yrtph.2024.105743_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1293\/tox.16.267","article-title":"Historical background data in CB6F1-Tg-rasH2 mice and CB6F1 - nonTg-rasH2 mice over a 26 week experimental period","author":"Kanno","year":"2003","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib22","first-page":"82","article-title":"Historical background data in CB6F1-Tg-rasH2 mice and CB6F1-nonTg-rasH2 mice over a 26-week experimental period","volume":"47","author":"Kanno","year":"2003","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/0192623318813143","article-title":"Comparison of the class effects of antisense oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 mice","volume":"47","author":"Kim","year":"2019","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib24","first-page":"21","article-title":"Growth, development, life span, and select lesion incidence in the Aging CD-1\u00ae mouse","volume":"1","author":"Lang","year":"1996","journal-title":"Pathobiology of the Aging Mouse"},{"key":"10.1016\/j.yrtph.2024.105743_bib25","series-title":"A Comprehensive Guide to Toxicology in Nonclinical Drug Development (Second Edition)","first-page":"273","author":"McCormick","year":"2017"},{"key":"10.1016\/j.yrtph.2024.105743_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/01926230252824851","article-title":"The Tg rasH2 mouse in cancer hazard identification","volume":"30","author":"Morton","year":"2002","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib27","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1177\/0192623313477257","article-title":"The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals","volume":"41","author":"Nambiar","year":"2013","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib44","series-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"2010"},{"key":"10.1016\/j.yrtph.2024.105743_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1091581812471565","article-title":"Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice","volume":"32","author":"Paranjpe","year":"2013","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105743_bib29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/0192623313478207","article-title":"Incidence of spontaneous non-neoplastic lesions in transgenic CBYB6F1-Tg(HRAS)2Jic mice","volume":"41","author":"Paranjpe","year":"2013","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib30","series-title":"Survival Analysis Using the SAS System: A Practical Guide","author":"PD","year":"1995"},{"key":"10.1016\/j.yrtph.2024.105743_bib31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.bbrc.2006.07.109","article-title":"Cell based screening of inhibitors of transthyretin aggregation","volume":"348","author":"Reixach","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yrtph.2024.105743_bib32","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yrtph.2024.105743_bib33","first-page":"845","article-title":"Malignant fibrous histiocytoma (MFH). A comparison of MFH in man and animals. A critical review","volume":"14","author":"Schneider","year":"1999","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib34","series-title":"Hereditary Transthyretin Amyloidosis. GeneReviews((R))","author":"Sekijima","year":"1993"},{"key":"10.1016\/j.yrtph.2024.105743_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","article-title":"Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm","volume":"13","author":"Sekijima","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yrtph.2024.105743_bib36","first-page":"191","article-title":"Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice","volume":"31","author":"Takaoka","year":"2003","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/01926230290105677","article-title":"Skeletal myopathy in transgenic mice carrying human prototype c-Ha-ras gene","volume":"30","author":"Tsuchiya","year":"2002","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/019262301753178500","article-title":"CB6F1-rasH2 mouse: overview of available data","volume":"29","author":"Usui","year":"2001","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2024.105743_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1515\/bmc-2013-0038","article-title":"Transthyretin: a multifaceted protein","volume":"5","author":"Vieira","year":"2014","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.yrtph.2024.105743_bib40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1091581810391818","article-title":"Differences in rat models used in routine toxicity studies","volume":"30","author":"Weber","year":"2011","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105743_bib41","series-title":"Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics. A Comprehensive Guide to Toxicology in Preclinical Drug Development","first-page":"647","author":"Younis","year":"2013"},{"key":"10.1016\/j.yrtph.2024.105743_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.112.197426","article-title":"Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2","volume":"343","author":"Zanardi","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.yrtph.2024.105743_bib43","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.120.000222","article-title":"Safety, pharmacokinetic and pharmacodynamic evaluation of a 2\u2019-MOE antisense oligonucleotide-GalNAc3 conjugate that targets the human transmembrane protease serine 6 (TMPRSS6)","volume":"377","author":"Zanardi","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T01:40:22Z","timestamp":1733967622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230024001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"alternative-id":["S0273230024001843"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105743","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carcinogenicity assessment of inotersen in Tg.rasH2 mice and Sprague-Dawley rats: Implications for 2\u2032-MOE antisense oligonucleotides","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105743"}}